Oncogenomics : from basic research to precision medicine /

Oncogenomics: From Basic Research to Precision Medicine offers a thorough survey of precision medicine and its diagnostic and therapeutic applications in oncology. Gathering contributions from leading international researchers in the field, chapters examine recent translational advances in oncogenom...

Full description

Bibliographic Details
Corporate Author: ScienceDirect (Online service)
Other Authors: Dammacco, Franco (Editor), Silvestris, Franco (Editor)
Format: eBook
Language:English
Published: London : Elsevier Ltd. : Academic Press, [2019]
Subjects:
Online Access:Connect to the full text of this electronic book
Table of Contents:
  • Front Cover
  • Oncogenomics
  • Copyright Page
  • Dedications
  • Contents
  • List of Contributors
  • Preface
  • I. Molecular medicine: a novel approach to cancer investigation
  • 1 From the Double Helix to Oncogenomics and Precision Cancer Medicine: An Evolving Story
  • Abbreviations
  • The Double Helix and the Human Genome Project
  • Precision Medicine Initiative and Precision Cancer Medicine
  • Oncogenomics in the Fight Against Cancer
  • Master Protocols and Clinical Trials of Targeted Drugs
  • NSCLC and Melanoma: Successful Examples of Precision Cancer Medicine
  • NSCLC
  • Melanoma
  • Precision Cancer Medicine: Uncertainties and Drawbacks
  • Conclusions
  • References
  • 2 Intratumor Heterogeneity: Biological and Clinical Implications
  • Introduction
  • Levels of Intratumor Heterogeneity
  • Genetic Heterogeneity
  • Transcriptomic and Proteomic Heterogeneity
  • Spatial Heterogeneity
  • Phenotypic Heterogeneity
  • Clinical Implications of Intratumor Heterogeneity and Novel Approaches
  • Conclusions
  • Acknowledgments
  • References
  • 3 The Role of Proteomics in Cancer Research
  • What Is a Proteome?
  • Proteomics Approaches in Cancer Research
  • The Role of Proteomics in Cancer Research
  • Advantages of the Proteome in Understanding the Biology of Cancer
  • Applying Proteomics Tools for Cancer Research
  • Post-translational Modifications in Cancer
  • Tumor Biomarkers and Liquid Biopsy
  • Monitoring Drug Effects With Proteomics
  • Conflict of Interest
  • References
  • Further Reading
  • 4 Next-Generation Sequencing in Clinical Practice
  • References
  • Further Reading
  • 5 Cancer Epigenetics: Aberrant DNA Methylation in Cancer Diagnosis and Treatment
  • Introduction
  • DNA Methylation and Transcriptional Regulation
  • Alterations of DNA Methylation in Cancer Cells
  • The CpG Island Methylator Phenotype.
  • Therapies Targeting Hedgehog and Notch Signaling in Cancer Stem Cells
  • Hedgehog Pathway Antagonists
  • Notch Pathway Antagonists
  • Conclusions and Future Perspectives
  • References
  • 9 Cancer Stem Cells in Multiple Myeloma and the Development of Novel Therapeutic Strategies
  • Abbreviations
  • Introduction
  • Multiple Myeloma Cancer Stem Cells: General Concepts
  • Clonotypic B Cells
  • Clonogenic Plasma Cells
  • Interconversion Between Differentiated and Undifferentiated Clonotypic Cells
  • Side Population Cells
  • Drug Resistance
  • Signaling Pathways
  • MicroRNAs
  • Bone Marrow Microenvironment
  • Targeting Multiple Myeloma Cancer Stem Cells
  • Conclusions
  • References
  • II. Oncogenomics: Circulating Biomarkers in Clinical Oncology
  • 10 Bone Metastases from Solid Tumors: In Search of Predictive Biomarkers for Clinical Translation
  • Abbreviations
  • Introduction
  • Epidemiological and Clinical Features of Bone Metastases
  • Pathogenesis of Bone Metastases
  • The "Omics Sciences" in the Prediction of Bone Metastases From Most Common Solid Cancers
  • In Search of a "Genomic Osteotropism Signature" in Solid Tumors
  • Prediction of Bone Metastases: A Clinical and Socioeconomic Issue
  • Conclusions
  • References
  • 11 Liquid Biopsy and Genomic Assessment for Lung Cancer: The Role in Clinical Practice?
  • Introduction
  • Which Biological Source?
  • Importance of the Preanalytical Steps for the Reliability of the Results
  • Which Analytical Platform for Which Evaluation?
  • Targeted Evaluation of Mutations in EGFR
  • Targeted Investigation Into Genomic Alterations Other That Those Present in EGFR
  • Detection With a Selected Panel of Genes
  • Perspectives and Conclusion
  • References
  • 12 Prognostic and Predictive Role of Circulating Tumor Cells
  • Introduction
  • CTC Isolation and Detection
  • Prognostic Role of CTCs in Solid Tumors.
  • Enumeration and Analysis of CTCs to Predict Treatment Response in Solid Tumors
  • Clinical Utility of CTCs: Current Status and Future Directions
  • References
  • 13 Circulating miRNAs as Tumor Biomarkers
  • MicroRNAs: Biosynthesis and Function
  • miRNAs Dysregulated in Cancer
  • Extracellular Vesicles and Extracellular miRNAs
  • Circulating miRNAs as Potential Biomarkers for Cancers
  • Breast Cancer
  • Colorectal Cancer
  • Lung Cancer
  • Pancreatic Cancer
  • Challenges and Opportunities for miRNA Based Biomarkers
  • Acknowledgments
  • References
  • 14 Circulating DNA in Cancer Diagnosis and Prognosis
  • Introduction
  • Circulating Cell-Free DNA
  • Circulating Tumor DNA (ctDNA)
  • Circulating DNA Levels in Patients With Cancer
  • Circulating Mutant Tumor DNA
  • Presence of Mutant Circulating Tumor DNA as a Prognostic Marker
  • Mutant Circulating Tumor DNA to Identify Therapy Sensitive or Resistant Cancer Subpopulations
  • Direct Comparison of Cancer Tissue DNA Mutations and Circulating Tumor DNA Mutations
  • Healthy Cells Can Take Up Mutant ctDNA
  • Copy Number Variations in Circulating Tumor DNA
  • Gene Methylation in Circulating Tumor DNA
  • Conclusions
  • References
  • 15 Sequencing a Single Circulating Tumor Cell for Genomic Assessment
  • Single-Cell Whole-Genome Sequencing Technologies
  • Isolation of a Single CTC
  • Single-Cell Whole-Genome Amplification Methods
  • Linker Adapter PCR
  • Primer Extension Preamplification PCR
  • Degenerate Oligonucleotide-Primed Polymerase Chain Reaction
  • Multiple Displacement Amplification
  • Multiple Annealing and Looping-Based Amplification Cycles
  • Single CTC NGS for Genetic Study of CTCs and Clinical Applications
  • Challenges and Future Prospects
  • References
  • 16 Single Nucleotide Polymorphisms in Cancer Research and Treatment
  • Introduction.
  • Potential Applications of SNPs in Oncology: Tumor Susceptibility
  • Potential Applications of Snps in Oncology: Association With Prognosis
  • Potential Applications of SNPs in Oncology: Association With Treatment Outcome
  • References
  • III. Gastrointestinal tumors: molecular diagnosis and treatment
  • 17 Gastric Cancers: A Molecular Roadmap for Patient Stratification and Targeted Therapies
  • Introduction
  • Molecular Classification of Gastroesophageal Cancer
  • Microsatellite Instability as a Biomarker
  • Immuno-oncology Agent Biomarkers
  • Current and Potential Targeted Therapeutic Strategies
  • Receptor Tyrosine Kinase (RTK) Amplifications
  • Targeting DNA Damage Repair (DDR) Pathways
  • Antiangiogenesis Therapies
  • Immune Checkpoint Inhibition
  • Other Molecular Targets of Interest in Gastrointestinal Adenocarcinomas
  • Future Directions
  • References
  • Further Reading
  • 18 Resistance to EGFR Targeting Treatments in Colorectal Cancer
  • Anti-EGFR Therapeutic Strategies in Colorectal Cancer
  • Resistance to Anti-EGFR Therapies: Heterogeneity Matters
  • Mechanisms of Resistance
  • Mutations
  • Epigenetic Abnormalities
  • Microenvironment
  • Signaling Reactivation and Pathway Bypass
  • Conclusions
  • Acknowledgment
  • References
  • 19 Circulating DNA and Protein Biomarkers for the Treatment of Metastatic Colorectal Cancer with Tyrosine Kinase Inhibitors
  • Introduction
  • Mutational profiles and targeted therapies in metastatic colorectal cancer
  • TKIs and monoclonal antibodies in metastatic Colorectal Cancer
  • Tissue testing
  • Liquid biopsies in metastatic colorectal cancer
  • Circulating cell-free DNA in metastatic colorectal cancer
  • Plasma protein biomarkers to monitor the effect of TKI in metastatic colorectal cancer
  • Further research and the way forward
  • References
  • 20 Rationale for Immunotherapy in Gastrointestinal Malignancies.